Literature DB >> 26409251

Two-group time-to-event continual reassessment method using likelihood estimation.

Amber Salter1, John O'Quigley2, Gary R Cutter3, Inmaculada B Aban3.   

Abstract

The presence of patient heterogeneity in dose finding studies is inherent (i.e. groups with different maximum tolerated doses). When this type of heterogeneity is not accounted for in the trial design, subjects may be exposed to toxic or suboptimal doses. Options to handle patient heterogeneity include conducting separate trials or splitting the trial into arms. However, cost and/or lack of resources may limit the feasibility of these options. If information is shared between the groups, then both of these options do not benefit from using the shared information. Extending current dose finding designs to handle patient heterogeneity maximizes the utility of existing methods within a single trial. We propose a modification to the time-to-event continual reassessment method to accommodate two groups using a two-parameter model and maximum likelihood estimation. The operating characteristics of the design are investigated through simulations under different scenarios including the scenario where one conducts two separate trials, one for each group, using the one-sample time-to-event continual reassessment method.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Continual reassessment method; Dose finding; Maximum likelihood; Patient heterogeneity; Phase I trial; Time-to-event

Mesh:

Year:  2015        PMID: 26409251     DOI: 10.1016/j.cct.2015.09.016

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  3 in total

1.  Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.

Authors:  Xiaoqiang Xue; Matthew C Foster; Anastasia Ivanova
Journal:  J Biopharm Stat       Date:  2019-06-28       Impact factor: 1.051

Review 2.  Challenges, opportunities, and innovative statistical designs for precision oncology trials.

Authors:  Jun Yin; Shihao Shen; Qian Shi
Journal:  Ann Transl Med       Date:  2022-09

3.  Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.

Authors:  Alexandra Curtis; Brian Smith; Andrew G Chapple
Journal:  Stat Med       Date:  2022-04-16       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.